(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...